Robert Baughman
Pulmonary Disease · Cincinnati, OHNPI 1417912783
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $548,600 of the $639,821 with a category attached, or 85.7%. Mallinckrodt Hospital Products Inc. accounts for 81.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $162,765 and has fallen 79.2% since, to $33,908 in 2025. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 367 payments — averaging $1743.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$519K
- Mallinckrodt Enterprises LLC$56K
- Boehringer Ingelheim$30K
- United Therapeutics Corporation$18K
- Actelion Pharmaceuticals, Ltd$9K
- AbbVie$5K
- plus $3K from 5 others
Across 18 payments — averaging $25,749 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Enterprises LLC$224K
- Bayer$102K
- Genentech, Inc.$98K
- Janssen Research & Development, LLC$17K
- Actelion Pharmaceuticals, Ltd$15K
- Bristol Myers Squibb$5K
- plus $1K from 2 others
What the payments were for
- Consulting fees$28,0544%
- Speaking & faculty fees$548,60086%
- Travel & lodging$54,7869%
- Food & beverage$8,3381%
- Education$30%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 278 | $518,503 |
| Mallinckrodt Enterprises LLC | 40 | $56,392 |
| Boehringer Ingelheim | 19 | $30,432 |
| United Therapeutics Corporation | 17 | $18,272 |
| Actelion Pharmaceuticals, Ltd | 3 | $8,700 |
| AbbVie | 3 | $4,513 |
| CSL Behring | 1 | $2,771 |
| Actelion Pharmaceuticals US, Inc. | 1 | $103 |
| Janssen Research & Development, LLC | 3 | $67 |
| Merck | 1 | $51 |
| Bayer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$639,821 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Cincinnati
- Bruce CorserCincinnati$502K
- Mohammad SheattCincinnati$389K
- Jean ElwingCincinnati$320K
- Bruce TrapnellCincinnati$92K
- Arun JoseCincinnati$56K
- Francis McCormackCincinnati$19K
- Joseph KhabbazaAkron$655K
- Kristin HighlandCleveland$551K
- Jason StieneckerLima$397K
- Mohammad KhanAkron$388K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.